These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23033227)

  • 1. Performance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds.
    Frey S; Stargardt T
    Pharmacotherapy; 2012 Oct; 32(10):880-9. PubMed ID: 23033227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.
    Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
    Med Care; 2008 Nov; 46(11):1125-33. PubMed ID: 18953222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study.
    Ward A; Ishak K; Proskorovsky I; Caro J
    Clin Ther; 2006 Nov; 28(11):1912-21. PubMed ID: 17213012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
    Jiang Y; Ni W
    Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany.
    Stargardt T; Edel MA; Ebert A; Busse R; Juckel G; Gericke CA
    J Clin Psychopharmacol; 2012 Oct; 32(5):602-7. PubMed ID: 22926592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia.
    Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
    Value Health; 2009 Sep; 12(6):989-95. PubMed ID: 19402852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.
    Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
    Curr Med Res Opin; 2009 Sep; 25(9):2303-10. PubMed ID: 19635045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of refill adherence and health care use among adults with hypertension in an urban health care system.
    Stroupe KT; Teal EY; Tu W; Weiner M; Murray MD
    Pharmacotherapy; 2006 Jun; 26(6):779-89. PubMed ID: 16716131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.
    Lang K; Federico V; Muser E; Menzin J; Menzin J
    J Med Econ; 2013 Aug; 16(8):997-1006. PubMed ID: 23777223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data.
    Rijcken CA; Tobi H; Vergouwen AC; de Jong-van den Berg LT
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):365-70. PubMed ID: 15170765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
    Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
    J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic, pharmacy-based, and self-reported health measures in risk equalization models.
    Stam PJ; van Vliet RC; van de Ven WP
    Med Care; 2010 May; 48(5):448-57. PubMed ID: 20393368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims.
    McHorney CA; Victor Spain C; Alexander CM; Simmons J
    Clin Ther; 2009 Nov; 31(11):2584-607. PubMed ID: 20110004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.